- Stocks
- Pharma & Healthcare
- Indegene
Indegene share price
NSE: INDGNPharma & HealthcareHealth Information Services
Indegene at a glance
Indegene (NSE: INDGN) closed at ₹577.95 on 22 Oct 2026, down 1.15% on the day. With a market capitalisation of ₹13,926 Cr, it ranks 462nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Health Information Services.
At its last close the stock traded at 34.8× trailing earnings, against a return on equity of 12.8% in FY26. Over the past year the share price has risen 8.6%. Its 52-week range is ₹414.50 (23 Mar 2026) to ₹627.00 (29 Sep 2026); the last close is 7.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,063 Cr (+39.7% year on year) and net profit ₹116 Cr (−0.2%), on a consolidated basis.
Key numbers
- Market cap
- ₹13,926 CrRank 462 on NSE
- P/E (trailing)
- 34.8×
- Price to book
- 3.33×FY26
- EPS (TTM)
- ₹16.71to Q1 FY27
- ROE
- 12.8%FY26
- ROCE
- 16.0%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 11.4%FY26
- Book value / share
- ₹130.51FY26
- 52-week high
- ₹627.0029 Sep 2026
- 52-week low
- ₹414.5023 Mar 2026
- 1-year return
- +8.6%
- RSI (14-day)
- 44.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.15% | −2.5% | −2.9% | +17.3% | +8.6% |
Indegene quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹687 Cr | ₹720 Cr | ₹756 Cr | ₹761 Cr | ₹804 Cr | ₹942 Cr | ₹1,003 Cr | ₹1,063 Cr |
| Revenue YoY | +8.0% | +7.0% | +12.3% | +12.5% | +17.1% | +30.8% | +32.8% | +39.7% |
| Net profit | ₹92 Cr | ₹110 Cr | ₹118 Cr | ₹116 Cr | ₹102 Cr | ₹103 Cr | ₹80 Cr | ₹116 Cr |
| Net profit YoY | +22.3% | +11.4% | +24.1% | +32.7% | +11.3% | −6.2% | −32.2% | −0.2% |
| Net margin | 13.4% | 15.2% | 15.6% | 15.3% | 12.7% | 10.9% | 7.9% | 10.9% |
| EPS | ₹3.84 | ₹4.59 | ₹4.91 | ₹4.86 | ₹4.26 | ₹4.29 | ₹3.32 | ₹4.84 |
Indegene financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | — | ₹1,665 Cr | ₹2,306 Cr | ₹2,590 Cr | ₹2,839 Cr | ₹3,511 Cr |
| Operating profit | — | ₹273 Cr | ₹363 Cr | ₹456 Cr | ₹539 Cr | ₹545 Cr |
| Net profit | — | ₹163 Cr | ₹266 Cr | ₹337 Cr | ₹407 Cr | ₹401 Cr |
| EPS (₹) | — | ₹8.00 | ₹12.00 | ₹15.00 | ₹17.00 | ₹17.00 |
| Cash from operations | — | ₹297 Cr | ₹130 Cr | ₹508 Cr | ₹442 Cr | ₹651 Cr |
| Total debt | ₹18 Cr | ₹11 Cr | ₹394 Cr | ₹333 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹325 Cr | ₹764 Cr | ₹1,064 Cr | ₹1,429 Cr | ₹2,615 Cr | ₹3,139 Cr |
Indegene shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Foreign institutions | 5.24% | 10.05% | 11.30% | 11.48% | 10.27% | 9.91% |
| Domestic institutions | 4.96% | 7.20% | 6.96% | 8.07% | 8.30% | 8.74% |
| Non-institutions | 89.80% | 82.75% | 81.74% | 80.45% | 81.44% | 81.34% |
Indegene vs peers
The listed Pharma & Healthcare companies nearest to Indegene by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| JUBLPHARMAJubilant Pharmova | ₹930.80 | −0.02% | −13.4% | ₹14,826 Cr | 37.1 | — |
| AGARWALEYEDr. Agarwal's Health Care | ₹459.10 | −1.51% | −10.7% | ₹14,553 Cr | — | — |
| VIJAYAVijaya Diagnostic Centre | ₹1,382.60 | +2.04% | +42.1% | ₹14,239 Cr | 82.5 | — |
| NATCOPHARMNatco Pharma | ₹785.00 | +0.13% | −3.3% | ₹14,060 Cr | 9.9 | — |
| INDGNIndegene | ₹577.95 | −1.15% | +8.6% | ₹13,926 Cr | 34.8 | — |
| CONCORDBIOConcord Biotech | ₹1,298.00 | +1.80% | −14.6% | ₹13,579 Cr | 52.4 | — |
| MARKSANSMarksans Pharma | ₹295.80 | −0.89% | +62.6% | ₹13,405 Cr | 32.1 | — |
Ask anything about Indegene
Pivot answers on the live chart with evidence you can check, and tests strategies against INDGN's own history. Try: “Why has INDGN moved over the last three months?” · “Backtest a 50-day moving-average crossover on INDGN over five years” · “Compare INDGN with JUBLPHARMA on margins and valuation”
Frequently asked questions about Indegene
What is the share price of Indegene today?
Indegene (NSE: INDGN) last closed at ₹577.95 on 22 Oct 2026. Its 52-week high is ₹627.00 and its 52-week low is ₹414.50.
What is the market cap of Indegene?
Indegene's market capitalisation is ₹13,926 Cr (₹13,926 Cr) at the 22 Oct 2026 close, ranking 462nd among the NSE companies Pivot tracks.
What is the P/E ratio of Indegene?
Indegene trades at a trailing P/E of 34.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 37.1.
What is the ROE and ROCE of Indegene?
Return on equity was 12.8% in FY26 and return on capital employed was 16.0% in FY26 (consolidated figures).
Is Indegene a debt-free company?
Indegene is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Indegene's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Indegene reported revenue of ₹1,063 Cr, +39.7% year on year, and net profit of ₹116 Cr, −0.2% year on year.
How has Indegene stock performed over the last year?
Indegene's share price has risen 8.6% over the past year, +17.3% over three months and −2.9% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Indegene?
As of 30 Jun 2026: foreign institutions 9.91%, domestic institutions 8.74%, non-institutions 81.34%.
Who are Indegene's competitors?
The listed Pharma & Healthcare companies closest to Indegene by market cap are Jubilant Pharmova, Dr. Agarwal's Health Care, Vijaya Diagnostic Centre, Natco Pharma, Concord Biotech and Marksans Pharma.
Is Indegene a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Indegene's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDGN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with I · all NSE stocks · this page as text